AA
ZYNE

ALPS Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

ALPS Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-36,356
Closed -$316K – 975
2018
Q1 		$316K Buy
36,356
+21,337
+142% +$230K ﹤0.01% 811
2017
Q4 		$188K Buy
15,019
+1,969
+15% +$22.6K ﹤0.01% 832
2017
Q3 		$109K Buy
13,050
+1,091
+9% +$11.5K ﹤0.01% 764
2017
Q2 		$12K Buy
+11,959
New +$238K ﹤0.01% 767

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ALPS Advisors's ZYNE Position: Q2 2018 in Review

ALPS Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2018, closing a stake of 36,356 shares — an estimated $316K sold.

ALPS Advisors first reported a position in ZYNE in Q2 2017 and held it in 4 quarters. The position peaked at $316K in Q1 2018. 59 funds tracked by Wall St. Rank hold ZYNE as of Q2 2018.

  • ALPS Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2018 after selling out during the quarter.
  • ALPS Advisors sold 36,356 Zynerba Pharmaceuticals, Inc shares in Q2 2018, an estimated $316K.
  • ALPS Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2017 and held it in 4 quarters.
  • ALPS Advisors's Zynerba Pharmaceuticals, Inc position peaked at $316K in Q1 2018.
  • 59 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2018.

Based on ALPS Advisors's 13F filing for Q2 2018, filed 25 Jul 2018.